2例伴有原发性BRCA-2突变的胰腺癌同步肝转移患者的长期完全缓解。

IF 1.3 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY Acta gastro-enterologica Belgica Pub Date : 2024-10-01 DOI:10.51821/87.4.11787

L Crapé, K Geboes, K Kortbeek, E Naert, A Hoorens, F Berrevoet, N Van Heddeghem, S Ribeiro

{"title":"2例伴有原发性BRCA-2突变的胰腺癌同步肝转移患者的长期完全缓解。","authors":"L Crapé, K Geboes, K Kortbeek, E Naert, A Hoorens, F Berrevoet, N Van Heddeghem, S Ribeiro","doi":"10.51821/87.4.11787","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic ductal adenocarcinoma (PDAC) has a known poor prognosis. For a select group, those with BRCA mutations, frontline platinum-based therapy and poly (ADPribose) polymerase inhibitors are options that can potentially lead to survival benefit.Patients and methods: We present 2 cases of patients with BRCAmutated pancreatic cancer with liver metastases that achieved a remarkable long-term complete remission on platinum-based chemotherapy.Conclusion: Germline testing for BRCA is important in PDAC because it influences treatment choices that impact survival. Complete responses with chemotherapy alone are rarely observed in metastatic PDAC, but may be seen upon treatment with platinum-based therapy.","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"87 4","pages":"521-523"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term complete remission of two patients with synchronous liver metastasis from pancreatic cancer and underlying BRCA-2 mutation.\",\"authors\":\"L Crapé, K Geboes, K Kortbeek, E Naert, A Hoorens, F Berrevoet, N Van Heddeghem, S Ribeiro\",\"doi\":\"10.51821/87.4.11787\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Pancreatic ductal adenocarcinoma (PDAC) has a known poor prognosis. For a select group, those with BRCA mutations, frontline platinum-based therapy and poly (ADPribose) polymerase inhibitors are options that can potentially lead to survival benefit.Patients and methods: We present 2 cases of patients with BRCAmutated pancreatic cancer with liver metastases that achieved a remarkable long-term complete remission on platinum-based chemotherapy.Conclusion: Germline testing for BRCA is important in PDAC because it influences treatment choices that impact survival. Complete responses with chemotherapy alone are rarely observed in metastatic PDAC, but may be seen upon treatment with platinum-based therapy.\",\"PeriodicalId\":7322,\"journal\":{\"name\":\"Acta gastro-enterologica Belgica\",\"volume\":\"87 4\",\"pages\":\"521-523\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta gastro-enterologica Belgica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.51821/87.4.11787\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastro-enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.51821/87.4.11787","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：胰导管腺癌（Pancreatic ductal adencarcinoma， PDAC）预后不良。对于一组有BRCA突变的患者，一线铂基治疗和聚（ADPribose）聚合酶抑制剂是可能导致生存获益的选择。患者和方法：我们报告了2例brcamated胰腺癌合并肝转移的患者，他们在铂类化疗中获得了显著的长期完全缓解。结论：BRCA的生殖系检测在PDAC中很重要，因为它影响治疗选择，影响生存。单纯化疗的完全缓解在转移性PDAC中很少观察到，但在铂基治疗中可能会看到。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Long-term complete remission of two patients with synchronous liver metastasis from pancreatic cancer and underlying BRCA-2 mutation.

Background: Pancreatic ductal adenocarcinoma (PDAC) has a known poor prognosis. For a select group, those with BRCA mutations, frontline platinum-based therapy and poly (ADPribose) polymerase inhibitors are options that can potentially lead to survival benefit.

Patients and methods: We present 2 cases of patients with BRCAmutated pancreatic cancer with liver metastases that achieved a remarkable long-term complete remission on platinum-based chemotherapy.

Conclusion: Germline testing for BRCA is important in PDAC because it influences treatment choices that impact survival. Complete responses with chemotherapy alone are rarely observed in metastatic PDAC, but may be seen upon treatment with platinum-based therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta gastro-enterologica Belgica Medicine-Gastroenterology

CiteScore

2.30

自引率

20.00%

发文量

期刊介绍： The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.